At a glance
ClinicalIndex Comparison RecordN/ACompleted· 539 enrolled
Drug / intervention
FINEVISION HP IOL +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Investigation of the Safety and Effectiveness of FINEVISION HP Trifocal IOL
In Brief
A clinical study evaluating FINEVISION HP IOL and Alcon AcrySof SN60AT for Eye Diseases and 3 related conditions. Completed, enrolled 539 participants across 20 sites.
Detailed Summary
This study is a prospective, multicenter, randomized, double masked confirmatory trial comparing an investigational trifocal intraocular lens (IOL) and a commercially available monofocal IOL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEye Diseases, Postcataract Aphakia, Cataract, Lens Opacities
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedNov 2019
Enrollment StartApr 2022
Primary CompletionMay 2024
TodayJul 2026
First PostedNov 26, 2019
Enrollment StartApr 28, 2022
Primary CompletionMay 13, 2024
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.6 years ago
Interventions
FINEVISION HP IOLdevice
Cataractous lens will be removed in the study eyes and the FINEVISION HP IOL will be implanted in the capsular bag.
Alcon AcrySof SN60ATdevice
Cataractous lens will be removed in the study eyes and the Alcon AcrySof SN60AT IOL will be implanted in the capsular bag.